WO2003060145A3 - Compositions and methods relating to pancreatic specific genes and proteins - Google Patents
Compositions and methods relating to pancreatic specific genes and proteins Download PDFInfo
- Publication number
- WO2003060145A3 WO2003060145A3 PCT/US2002/040655 US0240655W WO03060145A3 WO 2003060145 A3 WO2003060145 A3 WO 2003060145A3 US 0240655 W US0240655 W US 0240655W WO 03060145 A3 WO03060145 A3 WO 03060145A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptides
- pancreatic
- compositions
- antagonists
- agonists
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 239000000556 agonist Substances 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 238000012544 monitoring process Methods 0.000 abstract 2
- 210000004923 pancreatic tissue Anatomy 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic pancreatic cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating pancreatic cancer and non-cancerous disease states in pancreatic, identifying pancreatic tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered pancreatic tissue for treatment and research.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002366998A AU2002366998A1 (en) | 2001-12-21 | 2002-12-19 | Compositions and methods relating to pancreatic specific genes and proteins |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34276801P | 2001-12-21 | 2001-12-21 | |
| US60/342,768 | 2001-12-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2003060145A2 WO2003060145A2 (en) | 2003-07-24 |
| WO2003060145A3 true WO2003060145A3 (en) | 2004-07-08 |
Family
ID=23343196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2002/040655 WO2003060145A2 (en) | 2001-12-21 | 2002-12-19 | Compositions and methods relating to pancreatic specific genes and proteins |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002366998A1 (en) |
| WO (1) | WO2003060145A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009111471A2 (en) * | 2008-03-03 | 2009-09-11 | Henry Ford Health System | Collagen-derived peptide as biomarker, therapeutic agent and target |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001053836A2 (en) * | 2000-01-24 | 2001-07-26 | Millennium Pharmaceuticals, Inc. | Identification, assessment, prevention, and therapy of prostate cancer |
-
2002
- 2002-12-19 WO PCT/US2002/040655 patent/WO2003060145A2/en not_active Application Discontinuation
- 2002-12-19 AU AU2002366998A patent/AU2002366998A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001053836A2 (en) * | 2000-01-24 | 2001-07-26 | Millennium Pharmaceuticals, Inc. | Identification, assessment, prevention, and therapy of prostate cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002366998A1 (en) | 2003-07-30 |
| WO2003060145A2 (en) | 2003-07-24 |
| AU2002366998A8 (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004053079A3 (en) | Compositions, splice variants and methods relating to ovarian specific genes and proteins | |
| WO2002062945A3 (en) | Compositions and methods relating to lung specific genes and proteins | |
| WO2002055735A3 (en) | Compositions and methods relating to prostate specific genes and proteins | |
| WO2002064741A3 (en) | Compositions and methods relating to breast specific genes and proteins | |
| WO2002040673A3 (en) | Compositions and methods relating to lung specific genes and proteins | |
| WO2004053075A3 (en) | Compositions, splice variants and methods relating to breast specific genes and proteins | |
| WO2004050860A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| WO2005017102A3 (en) | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins | |
| WO2004013311A3 (en) | Compositions and methods relating to ovarian specific genes and proteins | |
| WO2003106648A3 (en) | Compositions and methods relating to breast specific genes and proteins | |
| WO2003066877A3 (en) | Compositions and methods relating to hepatic specific genes and proteins | |
| WO2004050858A3 (en) | Compositions, splice variants and methods relating to colon specific genes and proteins | |
| WO2002064788A3 (en) | Compositions and methods relating to lung specific genes and proteins | |
| WO2004052290A3 (en) | Compositions, splice variants and methods relating to breast specific genes and proteins | |
| WO2003020953A3 (en) | Compositions and methods relating to colon specific genes and proteins | |
| WO2003020899A3 (en) | Compositions and methods relating to lung specific genes and proteins | |
| WO2002042776A3 (en) | Compositions and methods relating to prostate specific genes and proteins | |
| WO2002039431A3 (en) | Compositions and methods relating to prostate specific genes and proteins | |
| WO2004053077A3 (en) | Compositions,splice variants and methods relating to breast specific genes and proteins | |
| WO2003020901A3 (en) | Compositions and methods relating to prostate specific genes and proteins | |
| WO2003060121A3 (en) | Compositions and methods relating to gastric specific genes and proteins | |
| WO2002046224A3 (en) | Compositions and methods relating to lung specific genes and proteins | |
| WO2003060081A3 (en) | Compositions and methods relating to endometrial specific genes and proteins | |
| WO2003055982A3 (en) | Compositions and methods relating to endometrial specific genes and proteins | |
| WO2002066605A3 (en) | Compositions and methods relating to breast specific genes and proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |